Kelleher Ruth, Bird Brian Healey, Hayes Tríona, O'Sullivan Crochan J
Department of Radiation Oncology, Cork University Hospital, Wilton Road, T12 DC4A Cork, Ireland.
Department of Oncology, Bon Secours Hospital Cork, College Road, Cork, Ireland.
Eur Heart J Case Rep. 2023 Dec 23;8(1):ytad635. doi: 10.1093/ehjcr/ytad635. eCollection 2024 Jan.
Primary cardiac lymphoma (PCL) is rare and its presentation can be variable. Thorough workup of suspected PCL or other cardiac tumours typically incorporates a range of imaging techniques and laboratory investigations but ultimately diagnosis is confirmed by histological analysis of myocardial tissue.
An 80-year-old Caucasian female presented with complete heart block and symptomatic cardiac tamponade. A pericardiocentesis was performed and a dual-chamber permanent pacemaker was implanted for the management of her complete heart block. Subsequently, a right atrial mass was discovered on imaging and the patient underwent endomyocardial biopsy of the mass. Histological analysis of the sample confirmed a primary cardiac lymphoma. The patient opted to forgo treatment with chemotherapy and died from her disease 1 month later.
Cardiac arrhythmias can occur in PCL due to infiltration of conduction pathways. Characterization of cardiac masses on various imaging modalities and laboratory tests guides diagnosis. Tissue diagnosis is required to confirm PCL. The location of a cardiac mass may present technical challenges when undertaking a biopsy, so the best approach to tissue sampling should be considered on an individual basis. Without treatment survival is less than one month but with modern chemoimmunotherapy five-year survival may exceed 50%.
原发性心脏淋巴瘤(PCL)较为罕见,其表现形式多样。对疑似PCL或其他心脏肿瘤进行全面检查通常需要一系列成像技术和实验室检查,但最终诊断需通过心肌组织的组织学分析来确认。
一名80岁的白人女性出现完全性心脏传导阻滞和有症状的心包填塞。进行了心包穿刺,并植入了双腔永久起搏器以治疗其完全性心脏传导阻滞。随后,影像学检查发现右心房有肿块,患者接受了该肿块的心内膜活检。样本的组织学分析证实为原发性心脏淋巴瘤。患者选择放弃化疗,1个月后死于该疾病。
由于传导通路受浸润,PCL可发生心律失常。通过各种成像方式和实验室检查对心脏肿块进行特征化有助于诊断。确诊PCL需要组织诊断。进行活检时,心脏肿块的位置可能带来技术挑战,因此应根据个体情况考虑最佳的组织采样方法。未经治疗,生存期不足1个月,但采用现代化学免疫疗法,五年生存率可能超过50%。